Back to search results

Moonshot Antibodies for Stage IV Cancers

This study is testing a new treatment called Moonshot antibodies for people with Stage IV soft tissue cancer, including breast, colon, lung, and other cancers. The goal is to see how safe Moonshot antibodies are and if they can help your body fight cancer. These antibodies are special because they are made in a lab using cells from your own tumor, so they are designed specifically for your cancer. First, doctors will take blood and tumor samples to create these unique antibodies. Then, you will receive the Moonshot antibodies through infusions. The main thing researchers are looking for is how often serious side effects happen over 6 months.

Study design
This is a Phase I, open-label study, meaning both you and your doctors will know what treatment you are receiving. Up to 16 people will participate across several study locations.
What's involved
You will provide blood and tumor samples, which may involve a biopsy if enough tissue isn't already available. After antibodies are made, you will receive them through a series of infusions.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored from your first dose of treatment through an evaluation at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06674538

Clinical Trial to Treat Stage IV Cancer Patients

Enrolling by Invitation
PHASE1Ages 18+InterventionalTreatment
Moonshot Antibodies
~12 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Moonshot antibodies

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety: Frequency of Grade III or greater adverse events
Measured over From first dose of treatment through endpoint evaluation at 6 months

Conditions

Soft Tissue Cancer

Explore related trials

Bladder CarcinomaBreast CarcinomaColon CarcinomaEsophageal CarcinomaGastric CarcinomaHematologic NeoplasmKidney CarcinomaLung CarcinomaLymphomaMalignant Head and Neck NeoplasmMalignant Ovarian NeoplasmMelanomaPancreatic CarcinomaProstate CarcinomaSarcomaSolid NeoplasmUrothelial CarcinomaCancer Cell Surface Proteins

NCT06674538

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Penn State Cancer Institute

    Hershey, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Krag, MD · STUDY_CHAIR · Moonshot Antibodies

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Safety: Frequency of Grade III or greater adverse eventsFrom first dose of treatment through endpoint evaluation at 6 months

    Frequency of Grade III or greater adverse events